Key facts
- Currus Biologics’s last known valuation is $21.6M (Oct 2025).
- It has raised $19.3M; the latest was Later Stage VC ($11.6M) in Oct 2025.
- Notable investors include Main Sequence Ventures, Brandon Capital, ANDHealth, Brandon Biocatalyst, Peter Maccallum Cancer Centre — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Currus Biologics
- ·The full record, as it builds
Funding rounds
No funding rounds for Currus Biologics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Currus Biologics
Developer of CAR-T cell therapies designed to treat solid cancers. The company specializes in bispecific antigen-presenting and T-cell engagers for the treatment of breast, colon, pancreatic, and prostate cancers to create chimeric antigen receptors that kill cancer cells with targeted and effective therapy, enabling patients to receive treatment for solid tumor indications.
- Sector
- Healthcare
- HQ
- Melbourne, Australia
- Founded
- 2020
- Employees
- 10
- Website
- currusbio.com/
- Ownership
- Privately Held (backing)
Currus Biologics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Currus Biologics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Currus Biologics in its N-PORT filings yet. We sweep new filings monthly.